Rivaroxaban ‘beneficial’ after revascularisation for claudication
Further results from the VOYAGER-PAD trial show use of the agent reduces major cardiovascular events
Patients who undergo lower extremity revascularisation for claudication and then have rivaroxaban have fewer major cardiovascular events than if they take placebo, researchers report.
The results come from a post-hoc sub-analysis of the VOYAGER-PAD trial, looking just at data for 5031 patients who had their revascularisation procedure for claudication.
